Slide 1: Phase 1 Single Ascending Dose Trial of ATI-2138: Preliminary Data
© Copyright 2022 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2022 Aclaris Therapeutics, Inc. All rights reserved November 8, 2022 EMPOWERING PATIENTS THROUGH KINOME INNOVATION Phase 1 Single Ascending Dose (SAD) Trial of ATI - 2138, an Investigational Oral Covalent ITK/TXK/JAK3 (ITJ)
Slide 2: Cautionary Note Regarding Forward-Looking Statements
© Copyright 2022 Aclaris Therapeutics, Inc. All rights reserved Any statements contained in this presentation that do not describe historical facts may constitute forward - looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be ide
Slide 3: ATI-2138: Covalent ITK/TXK/JAK3 (ITJ) Inhibitor with Potential for Ulcerative Colitis
© Copyright 2022 Aclaris Therapeutics, Inc. All rights reserved • ATI - 2138 covalently blocks ITK/TXK/JAK3 1 ➢ Potential for synergistic efficacy • ITK/TXK required for T cell receptor (TCR) signaling • JAK3 required for g c cytokines (IL - 2/4/7/9/15/21) ➢ PD effects persist after plasma clearance
Slide 4: Study Design
© Copyright 2022 Aclaris Therapeutics, Inc. All rights reserved Study Design Eligibility • Healthy subjects age ranging from 18 to 55 years, inclusive at screening • Minimum weight of 50 kg • Body mass index of 18 to 32 kg/m 2 , inclusive N=64 8 Cohorts 6 Active/2 Control per arm Objectives Primary
Slide 5: Preliminary Data
© Copyright 2022 Aclaris Therapeutics, Inc. All rights reserved • Safety ‒ ATI - 2138 was generally well tolerated at all doses tested in the trial. No serious adverse events or severe adverse events were reported. The most common adverse events in subjects treated with ATI - 2138, headache (four su
Slide 6: Simultaneous Stimulation of ITK and JAK3 Pathways Dose-Dependently Inhibited
© Copyright 2022 Aclaris Therapeutics, Inc. All rights reserved Simultaneous Stimulation of the ITK and JAK3 Pathways was Dose - Dependently Inhibited by ATI - 2138 6 Assesses modulation of both ITK and JAK3 via a CD3/IL - 15 - induced IFN g protein production Pharmacodynamic Dual Stimulation Assay